274 related articles for article (PubMed ID: 33086751)
21. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
[TBL] [Abstract][Full Text] [Related]
22. Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.
Sang S; Pan X; Chen Z; Zeng F; Pan S; Liu H; Jin L; Fei G; Wang C; Ren S; Jiao F; Bao W; Zhou W; Guan Y; Zhang Y; Shi H; Wang Y; Yu X; Wang Y; Zhong C
Alzheimers Res Ther; 2018 Mar; 10(1):26. PubMed ID: 29490669
[TBL] [Abstract][Full Text] [Related]
23. ApoE: the link between Alzheimer's-related glucose hypometabolism and Aβ deposition?
Patil SP; Ballard R; Sanchez S; Osborn J; Santangelo D
Med Hypotheses; 2012 Apr; 78(4):494-6. PubMed ID: 22285195
[TBL] [Abstract][Full Text] [Related]
24. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
25. Atypical Localization and Dissociation between Glucose Uptake and Amyloid Deposition in Cognitively Normal APOE*E4 Homozygotic Elders Compared with Patients with Late-Onset Alzheimer's Disease.
Pardo JV; Lee JT;
eNeuro; 2018; 5(1):. PubMed ID: 29497704
[TBL] [Abstract][Full Text] [Related]
26. Post-translational modifications of tau protein in Alzheimer's disease.
Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
J Neural Transm (Vienna); 2005 Jun; 112(6):813-38. PubMed ID: 15517432
[TBL] [Abstract][Full Text] [Related]
27. O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond.
Yuzwa SA; Vocadlo DJ
Chem Soc Rev; 2014 Oct; 43(19):6839-58. PubMed ID: 24759912
[TBL] [Abstract][Full Text] [Related]
28. A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model.
Capsoni S; Brandi R; Arisi I; D'Onofrio M; Cattaneo A
CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):635-47. PubMed ID: 21631402
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic approaches to Alzheimer's disease through stimulating of non-amyloidogenic processing of amyloid precursor protein.
Wang YQ; Qu DH; Wang K
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2389-403. PubMed ID: 27338066
[TBL] [Abstract][Full Text] [Related]
30. Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer's Disease Neuroimaging Initiative.
Koppel J; Sunday S; Goldberg TE; Davies P; Christen E; Greenwald BS;
Am J Geriatr Psychiatry; 2014 Jul; 22(7):698-707. PubMed ID: 23672944
[TBL] [Abstract][Full Text] [Related]
31. A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events.
Heininger K
Rev Neurosci; 2000; 11 Spec No():213-328. PubMed ID: 11065271
[TBL] [Abstract][Full Text] [Related]
32. O-GlcNAc modification in diabetes and Alzheimer's disease.
Dias WB; Hart GW
Mol Biosyst; 2007 Nov; 3(11):766-72. PubMed ID: 17940659
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
[TBL] [Abstract][Full Text] [Related]
34. Amyloid-β and glucose metabolism in Alzheimer's disease.
Furst AJ; Lal RA
J Alzheimers Dis; 2011; 26 Suppl 3():105-16. PubMed ID: 21971455
[TBL] [Abstract][Full Text] [Related]
35. Interplay between Alzheimer's disease and global glucose metabolism revealed by the metabolic profile alterations of pancreatic tissue and serum in APP/PS1 transgenic mice.
Liu X; Wang W; Chen HL; Zhang HY; Zhang NX
Acta Pharmacol Sin; 2019 Oct; 40(10):1259-1268. PubMed ID: 31089202
[TBL] [Abstract][Full Text] [Related]
36. The Y
Matrone C; Iannuzzi F; Annunziato L
Ageing Res Rev; 2019 Jul; 52():120-128. PubMed ID: 31039414
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model.
Baek H; Ye M; Kang GH; Lee C; Lee G; Choi DB; Jung J; Kim H; Lee S; Kim JS; Lee HJ; Shim I; Lee JH; Bae H
Oncotarget; 2016 Oct; 7(43):69347-69357. PubMed ID: 27713140
[TBL] [Abstract][Full Text] [Related]
38. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease.
Maczurek A; Shanmugam K; Münch G
Ann N Y Acad Sci; 2008 Apr; 1126():147-51. PubMed ID: 18448809
[TBL] [Abstract][Full Text] [Related]
39. The role of protein glycosylation in Alzheimer disease.
Schedin-Weiss S; Winblad B; Tjernberg LO
FEBS J; 2014 Jan; 281(1):46-62. PubMed ID: 24279329
[TBL] [Abstract][Full Text] [Related]
40. Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies.
Pinho TS; Correia SC; Perry G; Ambrósio AF; Moreira PI
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2048-2059. PubMed ID: 30412792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
